ABRAXANE meets primary endpoint in phase 3 trial for advanced non-small cell lung cancer
Researchers found those patients treated with ABRAXANE® and carboplatin demonstrated a significant improvement in overall tumour response rate compared with patients treated with a standard chemotherapy formulation containing TAXOL and carboplatin.
The Phase 3 trial was led by principal investigator Mark Socinski, M.D., at the University of North Carolina Lineberger Comprehensive Cancer Center, and is recognised as one of the largest NSCLC clinical studies to be conducted.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.